is imatinib appropriate treatment for acute lymphoblastic leukemia?
Residual issues in the therapy of Philadelphia chromosome-positive acute lymphoblastic leukemia. A number of very important questions remain about the role of our present therapies, standard combination chemotherapy, imatinib (or other TKI) and allogeneic HSCT, in the treatment of Ph+ ALL.